Calliditas Therapeutics AB Registered Shs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.02.21	Erste Schätzungen: Calliditas Therapeutics Registered informiert über die jüngsten Quartalsergebnisse (finanzen.net)
28.01.21	Calliditas announces termination of the proposed global offering (PR Newswire)
28.01.21	Calliditas announces termination of the proposed global offering (PR Newswire)
21.01.21	Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial (PR Newswire)
21.01.21	Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial (PR Newswire)
20.01.21	Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day (PR Newswire)
20.01.21	Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day (PR Newswire)
18.01.21	Positive Phase 1 results in high-dose setanaxib trial (PR Newswire)
18.01.21	Positive Phase 1 results in high-dose setanaxib trial (PR Newswire)
10.12.20	Calliditas wins the 2020 SwedenBio Award (PR Newswire)
10.12.20	Calliditas wins the 2020 SwedenBio Award (PR Newswire)
09.12.20	Save the date: Calliditas to host a Capital Markets Day in Stockholm, Sweden, on January 20, 2021 (PR Newswire)
09.12.20	Save the date: Calliditas to host a Capital Markets Day in Stockholm, Sweden, on January 20, 2021 (PR Newswire)
12.11.20	Interim Report Q3, 2020 (PR Newswire)
12.11.20	Interim Report Q3, 2020 (PR Newswire)
11.11.20	Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report (PR Newswire)
11.11.20	Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report (PR Newswire)
09.11.20	Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial (PR Newswire)
09.11.20	Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial (PR Newswire)
09.11.20	Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial (PR Newswire)
09.11.20	Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial (PR Newswire)
03.11.20	Calliditas closes acquisition of a controlling interest in Genkyotex SA (PR Newswire)
03.11.20	Calliditas closes acquisition of a controlling interest in Genkyotex SA (PR Newswire)
19.10.20	Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020 (PR Newswire)
19.10.20	Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020 (PR Newswire)
01.10.20	The 200th patient's last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020 (PR Newswire)
01.10.20	The 200th patient's last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020 (PR Newswire)
30.09.20	Number of shares and votes in Calliditas Therapeutics (PR Newswire)
30.09.20	Number of shares and votes in Calliditas Therapeutics (PR Newswire)
08.09.20	First patient in China enrolled in clinical phase 3 study NefIgArd with lead candidate Nefecon (PR Newswire)
08.09.20	First patient in China enrolled in clinical phase 3 study NefIgArd with lead candidate Nefecon (PR Newswire)
25.08.20	Calliditas appoints Group General Counsel (PR Newswire)
25.08.20	Calliditas appoints Group General Counsel (PR Newswire)
13.08.20	Calliditas Therapeutics: Interim Report Q2, 2020 (PR Newswire)
13.08.20	Calliditas Therapeutics: Interim Report Q2, 2020 (PR Newswire)
13.08.20	Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA (PR Newswire)
13.08.20	Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA (PR Newswire)
11.08.20	Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q2 report (PR Newswire)
11.08.20	Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q2 report (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Novartis	95.58	1.90 %	K V
Logitech Intl	91.48	1.35 %	K V
Part Grp Hldg	1’393.00	1.20 %	K V
Roche Hldg G	286.00	0.28 %	K V
Sonova Hldg	319.20	0.16 %	K V
Swiss Re	139.40	-0.50 %	K V
Zurich Insur Gr	553.80	-0.54 %	K V
Kuehne+Nagel Int	207.60	-0.76 %	K V
Lonza Grp	582.00	-1.49 %	K V
Nestle	77.48	-1.53 %	K V

Nachrichten zu Calliditas Therapeutics AB Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten